Medical/Pharmaceuticals News & Press Release Distribution

Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA

SUZHOU, China, June 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to envafolimab (KN035), a recombinant humanized PD-L1 single-domain antibody independently invented by Alphamab Onco...

2021-06-30 08:55 8370

GSK Singapore and Vir Biotechnology Announce Advance Purchase Agreement with the Government of Singapore for Monoclonal Antibody Sotrovimab (VIR-7831)

* GSK Singapore has signed an Advance Purchase Agreement with the Government ofSingapore for sotrovimab * Sotrovimab is currently undergoing review by the Singapore Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR) for interim authorization * Announcement follow...

2021-06-30 06:30 2319

GSK Singapore and Vir Biotechnology Announce Advance Purchase Agreement with the Government of Singapore for Monoclonal Antibody Sotrovimab (VIR-7831)

Cynosure Celebrates 30 Years of Innovation

Aesthetics leader recognizes milestone with focus on future skin aesthetics innovation to help reveal the Beautiful Energy within everyone WESTFORD, Mass., June 29, 2021 /PRNewswire/ -- Since 1991, Cynosure has been a leader in the beauty aesthetics space, creating a comprehensive range of exper...

2021-06-29 21:00 1412

Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"

SEOUL, South Korea, June 29, 2021 /PRNewswire/ -- Hanmi Pharmaceutical (hereinafter Hanmi) recently announced that its new, long-acting diabetes biologic drug, efpeglenatide, was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease in the resul...

2021-06-29 21:00 1548

Hanmi Pharmaceutical finds new innovative potential for

Cynosure Celebrates 30 Years of Innovation

Aesthetics leader recognizes milestone with focus on future skin aesthetics innovation to help reveal the Beautiful Energy within everyone WESTFORD, Mass., June 29, 2021 /PRNewswire/ -- Since 1991, Cynosure has been a leader in the beauty aesthetics space, creating a comprehensive range of exper...

2021-06-29 21:00 1719

European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients

Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage 2 melanoma patients BRUSSELS and CASTRES, France, June 29, 2021 /PRNewswire/ -- European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic part...

2021-06-29 20:13 1520

4G Clinical Announces $230MM Growth Equity Investment Backed by Goldman Sachs Asset Management

The innovative RTSM leader grew over 100% in 2020, plans to accelerate global expansion and support critical demand for products and services WELLESLEY, Mass. and NEW YORK, June 29, 2021 /PRNewswire/ -- 4G Clinical, a cutting-edge randomization and trial supply management (RTSM) company, announc...

2021-06-29 20:00 1419

I-Mab Announces Upcoming Participation at July Conference

SHANGHAI and GAITHERSBURG, Md., June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conference in July. D...

2021-06-29 20:00 8159

Medical Affairs Teams are Increasingly Turning to Patient-centric Analytics to Improve Clinical Outcomes

SANTA CLARA, Calif., June 29, 2021 /PRNewswire/ -- The shift to value-based care relies heavily on evidence-based medicine, and pharmaceutical companies play an important role in scientific communication across the healthcare ecosystem. Medical affairs experts interact with healthcare professiona...

2021-06-29 18:02 1120

Seegene unveils "MOBILE STATION," for on-site routine testing at public-use facilities and communities

* Seegene unveils "MOBILE STATION" at the Medlab Middle East 2021 * Mobile laboratory designed for mass testing at schools, airports, or communities, delivering test results within 3h 30min with the maximum testing capacity of 7,500 a day * The biotechnology firm to sign an MOU with G42 Heal...

2021-06-29 18:00 1512

Lianhua Qingwen Granted Market Access as Medicine in Ukraine: Yiling Pharmaceutical

SHIJIAZHUANG, China, June 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical disclosed in a statement on Monday that it had received the medicine registration document for Lianhua Qingwen Capsules from the Ministry of Health ofUkraine. As the leading product of Yiling Pharmaceutical, Lianhua Qingwen...

2021-06-29 16:41 2350

Innovent Announces License Agreement with Synaffix in an ADC Technology Deal

SAN FRANCISCO and SUZHOU, China, June 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-29 08:00 4533

Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2021

Added 19,367 New Subscribers in 4Q21 Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million) Net Income Attributable Up 31.7% YoY to RMB127.7 million ($19.5 million) Operating Cash Flow Up 134.6% YoY to RMB211.1 million ($32.2 million) Conference Call to be Held on June 29, 2021 at 8:00 a.m. ET HO...

2021-06-29 04:16 22374

First in China! Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON

* Novel and one-time intravitreal injection of ND4 gene therapy for the treatment of LHON potentially restored vision * Phase I/II/III clinical trial expected to enroll patients with LHON due to ND4 mutation WUHAN, China and SAN DIEGO, June 28, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd...

2021-06-28 21:33 1474

Pulnovo Medical: a Pulmonary Arterial Hypertension medical device company completed the world's first pulmonary hypertension treatment device RCT study after achieving FDA Breakthrough designation.

NANJING, China, June 28, 2021 /PRNewswire/ -- Recently, Pulnovo Medical's PADN-CFDA clinical trial, the world's first pulmonary hypertension treatment device RCT study, has completed all patients enrollment, and will continue to assist each enrollment center to complete the follow-up of enrolled ...

2021-06-28 21:16 1739

International experts join Microba Life Sciences inaugural IBD Advisory Panel

BRISBANE, Australia, June 28, 2021 /PRNewswire/ -- Precision microbiome science company,Microba Life Sciences , has appointed three respected key opinion leaders in Inflammatory Bowel Disease (IBD) to their IBD Advisory Panel to translate research into clinical outcomes f...

2021-06-28 21:00 1466

ILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury

DAEJEON, South Korea, June 28, 2021 /PRNewswire/ -- Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc. in collaboration withYonsei University of Seoul, South Korea. ...

2021-06-28 20:00 1287

New Late-Breaking Data at The American Diabetes Association Show GlycoMark® May Be an Effective Test for COVID-19 Severity

RALEIGH, N.C. and SAN SEBASTIAN, Spain, June 28, 2021 /PRNewswire/ -- Precision Diabetes, Inc. and Patia announced today results from a study showing that the GlycoMark blood test may be an effective marker of stress hyperglycemia and severity in COVID-19 patients, particularly in patients withou...

2021-06-28 19:00 981

RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study

Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity Opaganib's unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect agai...

2021-06-28 19:00 11220

InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL

BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the trea...

2021-06-28 16:02 10285